Abcon Therapeutics, Inc. is dedicated to the development of first-in-class therapeutics for T-cell mediated diseases and related cancers. The Company’s first product, ATX101, is a fully humanized monoclonal antibody-drug conjugate (ADC) that targets CD6, an established T cell marker. ATX101 has been highly effective in treating preclinical models of T-cell lymphoma (TCL), demonstrating tumor shrinkage and inhibition of tumor metastasis.